{"transactions":[{"id":671235,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":228000,"price":41.21,"value":9395880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":228000},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671234,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":313000,"price":48.14,"value":15067820.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":36.86,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":313000},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671233,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240000,"price":41.49,"value":9957600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671232,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":287700,"price":65.36,"value":18804072.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":287700},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671231,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":244205,"price":64.98,"value":15868440.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":244205},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671230,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":259058,"price":69.71,"value":18058933.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":15.29,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":259058},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671229,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":195578,"price":62.39,"value":12202111.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":22.61,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":195578},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671228,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":172281,"price":59.81,"value":10304126.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":25.19,"expiration_date":"2029-03-08","underlying":"Common Stock","underlying_shares":172281},"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671227,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":176663,"price":85,"value":15016355.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671226,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"price":85,"value":6800000.0,"ownership":{"direct":false,"nature":"By Charitable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671225,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":111100,"price":85,"value":9443500.0,"ownership":{"direct":false,"nature":"By Family Trust 8"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671224,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":111100,"price":85,"value":9443500.0,"ownership":{"direct":false,"nature":"By Family Trust 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671223,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":111100,"price":85,"value":9443500.0,"ownership":{"direct":false,"nature":"By Family Trust 6"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671222,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":111100,"price":85,"value":9443500.0,"ownership":{"direct":false,"nature":"By Family Trust 5"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671221,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"price":85,"value":8500000.0,"ownership":{"direct":false,"nature":"By Family Trust 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671220,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110000,"price":85,"value":9350000.0,"ownership":{"direct":false,"nature":"By Family Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671219,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":106000,"price":85,"value":9010000.0,"ownership":{"direct":false,"nature":"By Family Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671218,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136805,"price":85,"value":11628425.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671217,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"price":85,"value":85000.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":671216,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-09-01T20:52:50.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":248043,"price":85,"value":21083655.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":176663,"source":{"system":"sec-edgar","filing":"0001628280-26-059882","document":"wk-form4_1788295965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026059882/wk-form4_1788295965.xml","form_type":"4"}},{"id":690833,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":4995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the\nReporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":244205,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":4995},"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690832,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":6542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the\nReporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":259058,"derivative":{"exercise_price":15.29,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":6542},"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690831,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":4422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vested on March 24, 2020, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the\nReporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":195578,"derivative":{"exercise_price":22.61,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":4422},"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690830,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":3969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested monthly."}],"balance_after":172281,"derivative":{"exercise_price":25.19,"expiration_date":"2029-03-08","underlying":"Common Stock","underlying_shares":3969},"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690829,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":4995,"price":20.02,"value":99999.9,"ownership":{"direct":true},"balance_after":424706,"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690828,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":6542,"price":15.29,"value":100027.18,"ownership":{"direct":true},"balance_after":419711,"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690827,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":4422,"price":22.61,"value":99981.42,"ownership":{"direct":true},"balance_after":413169,"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":690826,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-08-11T20:11:18.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":3969,"price":25.19,"value":99979.11,"ownership":{"direct":true},"balance_after":408747,"source":{"system":"sec-edgar","filing":"0001628280-26-055700","document":"wk-form4_1786479075.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026055700/wk-form4_1786479075.xml","form_type":"4"}},{"id":754899,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 8"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"(3)\tRepresents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust (\"Family Trust 7\") and (b) the RSS Dynasty Trust (\"Family Trust 8\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":111100,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754898,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 7"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"(3)\tRepresents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust (\"Family Trust 7\") and (b) the RSS Dynasty Trust (\"Family Trust 8\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":111100,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754897,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"(3)\tRepresents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust (\"Family Trust 7\") and (b) the RSS Dynasty Trust (\"Family Trust 8\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754896,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"(3)\tRepresents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust (\"Family Trust 7\") and (b) the RSS Dynasty Trust (\"Family Trust 8\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":112100,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754895,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 6"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"(2)\tRepresents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust (\"Family Trust 5\") and (b) the JSS Dynasty Trust (\"Family Trust 6\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":111100,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754894,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"(2)\tRepresents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust (\"Family Trust 5\") and (b) the JSS Dynasty Trust (\"Family Trust 6\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":111100,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754893,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"(2)\tRepresents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust (\"Family Trust 5\") and (b) the JSS Dynasty Trust (\"Family Trust 6\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":404778,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754892,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"(2)\tRepresents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust (\"Family Trust 5\") and (b) the JSS Dynasty Trust (\"Family Trust 6\"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein."}],"balance_after":515878,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754891,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Charitable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tRepresents gifts of shares by the Struthers Family Trust (\"Family Trust 1\"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the \"Charitable Trust\"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754890,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":222200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tRepresents gifts of shares by the Struthers Family Trust (\"Family Trust 1\"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the \"Charitable Trust\"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein."}],"balance_after":223200,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754889,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":true,"shares":222200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tRepresents gifts of shares by the Struthers Family Trust (\"Family Trust 1\"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the \"Charitable Trust\"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein."}],"balance_after":626978,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754888,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tRepresents gifts of shares by the Struthers Family Trust (\"Family Trust 1\"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the \"Charitable Trust\"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein."}],"balance_after":136805,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754887,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":222200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tRepresents gifts of shares by the Struthers Family Trust (\"Family Trust 1\"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the \"Charitable Trust\"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein."}],"balance_after":216805,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":754886,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:18.000Z","date":"2026-05-29","kind":"gift","planned":false,"acquired":false,"shares":222200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tRepresents gifts of shares by the Struthers Family Trust (\"Family Trust 1\"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the \"Charitable Trust\"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein."}],"balance_after":439005,"source":{"system":"sec-edgar","filing":"0001628280-26-039784","document":"wk-form4_1780430656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026039784/wk-form4_1780430656.xml","form_type":"4"}},{"id":835037,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-18T21:05:33.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":8785,"price":37.77,"value":331809.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":404778,"source":{"system":"sec-edgar","filing":"0001628280-26-019488","document":"wk-form4_1773867929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026019488/wk-form4_1773867929.xml","form_type":"4"}},{"id":835036,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-18T21:05:33.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":13196,"price":37.11,"value":489703.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":413563,"source":{"system":"sec-edgar","filing":"0001628280-26-019488","document":"wk-form4_1773867929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026019488/wk-form4_1773867929.xml","form_type":"4"}},{"id":882067,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-25T21:37:01.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":228000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026."}],"balance_after":228000,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":228000},"source":{"system":"sec-edgar","filing":"0001628280-26-011730","document":"wk-form4_1772055418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026011730/wk-form4_1772055418.xml","form_type":"4"}},{"id":882066,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-02-25T21:37:01.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027."}],"balance_after":426759,"source":{"system":"sec-edgar","filing":"0001628280-26-011730","document":"wk-form4_1772055418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828026011730/wk-form4_1772055418.xml","form_type":"4"}},{"id":963197,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-18T23:54:46.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":false,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":259058,"derivative":{"exercise_price":15.29,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0001628280-25-058056","document":"wk-form4_1766102083.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828025058056/wk-form4_1766102083.xml","form_type":"4"}},{"id":963196,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-18T23:54:46.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":false,"shares":16342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":16342},"source":{"system":"sec-edgar","filing":"0001628280-25-058056","document":"wk-form4_1766102083.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828025058056/wk-form4_1766102083.xml","form_type":"4"}},{"id":963195,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-18T23:54:46.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":true,"shares":28400,"price":15.29,"value":434236.0,"ownership":{"direct":true},"balance_after":364759,"source":{"system":"sec-edgar","filing":"0001628280-25-058056","document":"wk-form4_1766102083.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828025058056/wk-form4_1766102083.xml","form_type":"4"}},{"id":963194,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-18T23:54:46.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":true,"shares":16342,"price":9.28,"value":151653.76,"ownership":{"direct":true},"balance_after":336359,"source":{"system":"sec-edgar","filing":"0001628280-25-058056","document":"wk-form4_1766102083.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000162828025058056/wk-form4_1766102083.xml","form_type":"4"}},{"id":1030613,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-09-30T20:42:56.000Z","date":"2025-09-26","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":45,"value":180000.0,"ownership":{"direct":false,"nature":"By Family Trust 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $45.00 per share."}],"balance_after":106000,"source":{"system":"sec-edgar","filing":"0001658247-25-000011","document":"wk-form4_1759264973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000165824725000011/wk-form4_1759264973.xml","form_type":"4"}},{"id":1145468,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-05-16T20:30:25.000Z","date":"2025-05-14","kind":"gift","planned":false,"acquired":true,"shares":90400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting person for no consideration."}],"balance_after":661205,"source":{"system":"sec-edgar","filing":"0000950170-25-073605","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025073605/ownership.xml","form_type":"4"}},{"id":1145467,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-05-16T20:30:25.000Z","date":"2025-05-14","kind":"gift","planned":false,"acquired":false,"shares":90400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting person for no consideration."}],"balance_after":320017,"source":{"system":"sec-edgar","filing":"0000950170-25-073605","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025073605/ownership.xml","form_type":"4"}},{"id":1177672,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-04T20:30:05.000Z","date":"2025-04-02","kind":"exercise","planned":false,"acquired":false,"shares":81270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":81270},"source":{"system":"sec-edgar","filing":"0000950170-25-051170","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025051170/ownership.xml","form_type":"4"}},{"id":1177671,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-04-04T20:30:05.000Z","date":"2025-04-02","kind":"exercise","planned":false,"acquired":true,"shares":81270,"price":1.91,"value":155225.7,"ownership":{"direct":true},"balance_after":410417,"source":{"system":"sec-edgar","filing":"0000950170-25-051170","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025051170/ownership.xml","form_type":"4"}},{"id":1194678,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-21T22:31:53.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":875,"price":34.83,"value":30476.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":329147,"source":{"system":"sec-edgar","filing":"0000950170-25-043401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025043401/ownership.xml","form_type":"4"}},{"id":1194677,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-21T22:31:53.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":16463,"price":34.17,"value":562540.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":330022,"source":{"system":"sec-edgar","filing":"0000950170-25-043401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025043401/ownership.xml","form_type":"4"}},{"id":1249647,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-24T21:30:10.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":313000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025."}],"balance_after":313000,"derivative":{"exercise_price":36.86,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":313000},"source":{"system":"sec-edgar","filing":"0000950170-25-025667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025025667/ownership.xml","form_type":"4"}},{"id":1249646,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-24T21:30:10.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":89000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026."}],"balance_after":346485,"source":{"system":"sec-edgar","filing":"0000950170-25-025667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017025025667/ownership.xml","form_type":"4"}},{"id":1343034,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-04T21:30:05.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":57.57,"value":575700.0,"ownership":{"direct":false,"nature":"By Family Trust 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $57.57 per share. The range of sales prices on the transaction date was $56.90 to $58.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000950170-24-133297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024133297/ownership.xml","form_type":"4"}},{"id":1520801,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-10T20:57:04.000Z","date":"2024-05-08","kind":"exercise","planned":true,"acquired":false,"shares":107448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":16342,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":107448},"source":{"system":"sec-edgar","filing":"0000950170-24-057926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024057926/ownership.xml","form_type":"4"}},{"id":1520800,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-10T20:57:04.000Z","date":"2024-05-08","kind":"sale","planned":true,"acquired":false,"shares":107448,"price":49.4,"value":5307931.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.40 per share. The range of sales prices on the transaction date was $48.95 to $50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":257485,"source":{"system":"sec-edgar","filing":"0000950170-24-057926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024057926/ownership.xml","form_type":"4"}},{"id":1520799,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-10T20:57:04.000Z","date":"2024-05-08","kind":"exercise","planned":true,"acquired":true,"shares":107448,"price":9.28,"value":997117.44,"ownership":{"direct":true},"balance_after":364933,"source":{"system":"sec-edgar","filing":"0000950170-24-057926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024057926/ownership.xml","form_type":"4"}},{"id":1537606,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-22T21:23:10.000Z","date":"2024-04-18","kind":"gift","planned":false,"acquired":false,"shares":350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting Person for no consideration."}],"balance_after":257485,"source":{"system":"sec-edgar","filing":"0000950170-24-046523","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024046523/ownership.xml","form_type":"4"}},{"id":1540030,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-17T20:30:22.000Z","date":"2024-04-15","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":81270,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-045136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024045136/ownership.xml","form_type":"4"}},{"id":1540029,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-17T20:30:22.000Z","date":"2024-04-15","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":1.91,"value":38200.0,"ownership":{"direct":true},"balance_after":257835,"source":{"system":"sec-edgar","filing":"0000950170-24-045136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024045136/ownership.xml","form_type":"4"}},{"id":1545738,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2024-04-08T21:09:38.000Z","date":"2024-04-04","kind":"exercise","planned":true,"acquired":false,"shares":40951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":123790,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":40951},"source":{"system":"sec-edgar","filing":"0000950170-24-042681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024042681/ownership.xml","form_type":"4"}},{"id":1545737,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-08T21:09:38.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":40951,"price":49.17,"value":2013560.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.17 per share. The range of sales prices on the transaction date was $48.95 to $49.56 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":237835,"source":{"system":"sec-edgar","filing":"0000950170-24-042681","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024042681/ownership.xml","form_type":"4"}},{"id":1545736,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-08T21:09:38.000Z","date":"2024-04-04","kind":"exercise","planned":true,"acquired":true,"shares":40951,"price":9.28,"value":380025.28,"ownership":{"direct":true},"balance_after":278786,"source":{"system":"sec-edgar","filing":"0000950170-24-042681","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000095017024042681/ownership.xml","form_type":"4"}},{"id":1566023,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-20T22:31:49.000Z","date":"2024-03-18","kind":"tax_withholding","planned":true,"acquired":false,"shares":12687,"price":38.14,"value":483882.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022 and March 1, 2023.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":237835,"source":{"system":"sec-edgar","filing":"0001209191-24-005008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124005008/doc4.xml","form_type":"4"}},{"id":1591804,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-07T01:01:02.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024."}],"balance_after":240000,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001209191-24-004608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124004608/doc4.xml","form_type":"4"}},{"id":1591803,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-07T01:01:02.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025."}],"balance_after":250522,"source":{"system":"sec-edgar","filing":"0001209191-24-004608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124004608/doc4.xml","form_type":"4"}},{"id":1643264,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-14T21:28:29.000Z","date":"2024-02-12","kind":"gift","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting Person for no consideration."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001209191-24-003354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124003354/doc4.xml","form_type":"4"}},{"id":1643263,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-14T21:28:29.000Z","date":"2024-02-12","kind":"gift","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting Person for no consideration."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001209191-24-003354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124003354/doc4.xml","form_type":"4"}},{"id":1643262,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-14T21:28:29.000Z","date":"2024-02-12","kind":"gift","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting Person for no consideration."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001209191-24-003354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124003354/doc4.xml","form_type":"4"}},{"id":1643261,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-14T21:28:29.000Z","date":"2024-02-12","kind":"gift","planned":false,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift made by the Reporting Person for no consideration."}],"balance_after":570805,"source":{"system":"sec-edgar","filing":"0001209191-24-003354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919124003354/doc4.xml","form_type":"4"}},{"id":1744029,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Incentive stock option (Right to Buy)","published_at":"2023-11-13T21:33:30.000Z","date":"2023-11-09","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":101270,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-055022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123055022/doc4.xml","form_type":"4"}},{"id":1744028,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-13T21:33:30.000Z","date":"2023-11-09","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":1.91,"value":95500.0,"ownership":{"direct":true},"balance_after":185522,"source":{"system":"sec-edgar","filing":"0001209191-23-055022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123055022/doc4.xml","form_type":"4"}},{"id":1748716,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2023-11-06T23:02:02.000Z","date":"2023-11-03","kind":"exercise","planned":true,"acquired":false,"shares":199082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":164741,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":199082},"source":{"system":"sec-edgar","filing":"0001209191-23-054567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123054567/doc4.xml","form_type":"4"}},{"id":1748715,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2023-11-06T23:02:02.000Z","date":"2023-11-02","kind":"exercise","planned":true,"acquired":false,"shares":918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":363823,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":918},"source":{"system":"sec-edgar","filing":"0001209191-23-054567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123054567/doc4.xml","form_type":"4"}},{"id":1748714,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-06T23:02:02.000Z","date":"2023-11-03","kind":"sale","planned":true,"acquired":false,"shares":199082,"price":30.56,"value":6083945.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $30.56 per share. The range of sales prices on the transaction date was $29.95 to $31.37 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":135522,"source":{"system":"sec-edgar","filing":"0001209191-23-054567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123054567/doc4.xml","form_type":"4"}},{"id":1748713,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-06T23:02:02.000Z","date":"2023-11-03","kind":"exercise","planned":true,"acquired":true,"shares":199082,"price":9.28,"value":1847480.96,"ownership":{"direct":true},"balance_after":334604,"source":{"system":"sec-edgar","filing":"0001209191-23-054567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123054567/doc4.xml","form_type":"4"}},{"id":1748712,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-06T23:02:02.000Z","date":"2023-11-02","kind":"sale","planned":true,"acquired":false,"shares":918,"price":29.95,"value":27494.1,"ownership":{"direct":true},"balance_after":135522,"source":{"system":"sec-edgar","filing":"0001209191-23-054567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123054567/doc4.xml","form_type":"4"}},{"id":1748711,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-06T23:02:02.000Z","date":"2023-11-02","kind":"exercise","planned":true,"acquired":true,"shares":918,"price":9.28,"value":8519.04,"ownership":{"direct":true},"balance_after":136440,"source":{"system":"sec-edgar","filing":"0001209191-23-054567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123054567/doc4.xml","form_type":"4"}},{"id":1805953,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Incentve stock option (Right to Buy)","published_at":"2023-08-16T20:30:15.000Z","date":"2023-08-14","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":151270,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-046024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123046024/doc4.xml","form_type":"4"}},{"id":1805952,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-08-16T20:30:15.000Z","date":"2023-08-14","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":1.91,"value":19100.0,"ownership":{"direct":true},"balance_after":135522,"source":{"system":"sec-edgar","filing":"0001209191-23-046024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123046024/doc4.xml","form_type":"4"}},{"id":1830340,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-07-13T20:56:59.000Z","date":"2023-07-13","kind":"sale","planned":true,"acquired":false,"shares":14157,"price":20.35,"value":288094.95,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.35 per share. The range of sales prices on the transaction date was $20.10 to $20.68 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":630805,"source":{"system":"sec-edgar","filing":"0001209191-23-042229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123042229/doc4.xml","form_type":"4"}},{"id":1830339,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-07-13T20:56:59.000Z","date":"2023-07-12","kind":"sale","planned":true,"acquired":false,"shares":11459,"price":20.17,"value":231128.03,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.17 per share. The range of sales prices on the transaction date was $20.10 to $20.31 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":644962,"source":{"system":"sec-edgar","filing":"0001209191-23-042229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123042229/doc4.xml","form_type":"4"}},{"id":1830338,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-07-13T20:56:59.000Z","date":"2023-07-11","kind":"sale","planned":true,"acquired":false,"shares":24384,"price":20.14,"value":491093.76,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.14 per share. The range of sales prices on the transaction date was $20.10 to $20.25 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request"}],"balance_after":656421,"source":{"system":"sec-edgar","filing":"0001209191-23-042229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123042229/doc4.xml","form_type":"4"}},{"id":1847912,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-06-21T21:27:50.000Z","date":"2023-06-16","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":20.81,"value":1040500.0,"ownership":{"direct":false,"nature":"By Family Trust 1"},"balance_after":680805,"source":{"system":"sec-edgar","filing":"0001209191-23-038851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123038851/doc4.xml","form_type":"4"}},{"id":1947189,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-17T21:10:27.000Z","date":"2023-03-16","kind":"tax_withholding","acquired":false,"shares":4628,"price":17.12,"value":79231.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":125522,"source":{"system":"sec-edgar","filing":"0001209191-23-019772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123019772/doc4.xml","form_type":"4"}},{"id":1974012,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock (right to buy)","published_at":"2023-03-03T21:31:33.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":287700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023."}],"balance_after":287700,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":287700},"source":{"system":"sec-edgar","filing":"0001209191-23-015524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123015524/doc4.xml","form_type":"4"}},{"id":1974011,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-03T21:31:33.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":61650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024."}],"balance_after":130150,"source":{"system":"sec-edgar","filing":"0001209191-23-015524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919123015524/doc4.xml","form_type":"4"}},{"id":2137093,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Incentive stock option (Right to Buy)","published_at":"2022-10-14T20:55:04.000Z","date":"2022-10-12","kind":"exercise","acquired":false,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":161270,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001209191-22-053680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122053680/doc4.xml","form_type":"4"}},{"id":2137092,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-10-14T20:55:04.000Z","date":"2022-10-12","kind":"exercise","acquired":true,"shares":11100,"price":1.91,"value":21201.0,"ownership":{"direct":true},"balance_after":68500,"source":{"system":"sec-edgar","filing":"0001209191-22-053680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122053680/doc4.xml","form_type":"4"}},{"id":2296419,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-15T22:00:14.000Z","date":"2022-04-13","kind":"sale","acquired":false,"shares":69176,"price":27.5277,"value":1904256.1752,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.5277 per share. The range of actual sales prices on the transaction date was $27.02 to $27.845 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request."}],"balance_after":730805,"source":{"system":"sec-edgar","filing":"0001209191-22-024531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122024531/doc4.xml","form_type":"4"}},{"id":2296418,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-15T22:00:14.000Z","date":"2022-04-13","kind":"sale","acquired":false,"shares":44793,"price":26.5229,"value":1188040.2597,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $26.5229 per share. The range of actual sales prices on the transaction date was $26.02 to $27.005 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request."}],"balance_after":799981,"source":{"system":"sec-edgar","filing":"0001209191-22-024531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122024531/doc4.xml","form_type":"4"}},{"id":2296417,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-15T22:00:14.000Z","date":"2022-04-13","kind":"sale","acquired":false,"shares":24674,"price":25.4247,"value":627329.0478,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.4247 per share. The range of actual sales prices on the transaction date was $25.00 to $25.98 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request."}],"balance_after":844774,"source":{"system":"sec-edgar","filing":"0001209191-22-024531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122024531/doc4.xml","form_type":"4"}},{"id":2301475,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-07T21:58:19.000Z","date":"2022-04-05","kind":"sale","acquired":false,"shares":21357,"price":25.3418,"value":541224.8226,"ownership":{"direct":false,"nature":"By Family Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.3418 per share. The range of actual sales prices on the transaction date was $25.00 to $25.57 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request."}],"balance_after":869448,"source":{"system":"sec-edgar","filing":"0001209191-22-023722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122023722/doc4.xml","form_type":"4"}},{"id":2361028,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17963,"kind":"person","name":"Struthers Richard Scott","position":1,"cik":"0001746298","reported_name":"Struthers Richard Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock (right to buy)","published_at":"2022-03-03T02:00:50.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":249200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022."}],"balance_after":249200,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":249200},"source":{"system":"sec-edgar","filing":"0001209191-22-015134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746298/000120919122015134/doc4.xml","form_type":"4"}}],"next_cursor":"2022-03-03T02:00:50.000000Z,2361028"}